CAMLINFINE:NSE-Camlin Fine Sciences Limited (INR)

COMMON STOCK | Specialty Chemicals | NSE

Last Closing Price

INR 175.35

Change

0.00 (0.00)%

Market Cap

INR 22.49B

Volume

0.42M

Average Target Price

INR 189.80 (+8.24%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Camlin Fine Sciences Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of specialty chemical and additive blend products in India, Mexico, Central and North America, China, Europe, Singapore, and South America. It offers shelf-life solutions, which include antioxidants comprises Tertiary Butyl Hydroquinone, Butylated Hydroxy Anisole, and Ascorbyl palmitate, as well as natural shelf life solution products, such as tocopherols, green tea extract, rosemary extract, and acerola extract that are used to enhance the shelf life for food and feed industry under the Xtendra and NaSure brands. The company also provides aroma ingredients, including vanillin and ethyl vanillin under the Vanesse and Evanil brands; and nutraceutical products from fermentation and green extraction sources, such as algal carotenoids, natural colors and vitamins, minerals and proteins, cosmetic ingredients, organic herbals, and probiotics. In addition, it offers performance chemicals, such as hydroquinone and catechol; and downstream fine chemicals, including Guaiacol, Veratrole, TBC, MEHQ, ODEB, CME, HQEE, etc. Further, the company manufactures and markets various animal nutrition products, antioxidants, adsorbents, acidifying agents, antimicrobials, bactericides, sanitizers, growth promoters, toxin and pellet binders, and mold inhibitors. It also exports its products. Its products are used in food and beverage, pet food and animal nutrition, rendering, aquaculture, biodiesel, flavor and fragrance, pharmaceutical, petrochemical, agrochemical, dyes and pigment, polymers, textile, printing, household and industrial products, telecommunications, and oil and gas industries. The company was formerly known as Camlin Fine Chemicals Limited and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India. Address: Plot No. F/11 & F/12, WICEL, Mumbai, India, 400093

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-13 )

Largest Industry Peers for Specialty Chemicals

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ASIANPAINT:NSE Asian Paints Limited

N/A

INR2,835.34B 90.29 53.85
PIDILITIND:NSE Pidilite Industries Limited

N/A

INR1,074.74B 95.10 61.33
BERGEPAINT:NSE Berger Paints India Limited

N/A

INR782.62B 108.74 63.43
SRF:NSE SRF Limited

N/A

INR418.86B 34.40 19.98
AARTIIND:NSE Aarti Industries Limited

N/A

INR316.38B 60.45 34.32
KANSAINER:NSE Kansai Nerolac Paints Limited

N/A

INR314.11B 59.29 34.27
ATUL:NSE Atul Ltd

N/A

INR261.85B 40.01 24.51
ALKYLAMINE:NSE Alkyl Amines Chemicals Limited

N/A

INR183.56B 62.32 41.96
SUMICHEM:NSE Sumitomo Chemical India Limite..

N/A

INR181.94B 52.68 34.94
VINATIORGA:NSE Vinati Organics Limited

N/A

INR177.77B 66.00 46.46

ETFs Containing CAMLINFINE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Specialty Chemicals)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.84% 57% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.84% 57% F 63% D
Trailing 12 Months  
Capital Gain 323.04% 93% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 323.04% 93% A 95% A
Trailing 5 Years  
Capital Gain 95.05% 42% F 67% D+
Dividend Return 0.50% 2% F 3% F
Total Return 95.55% 41% F 66% D
Average Annual (5 Year Horizon)  
Capital Gain 20.92% 62% D- 75% C
Dividend Return 0.01% 1% F 1% F
Total Return 20.94% 62% D- 75% C
Risk Return Profile  
Volatility (Standard Deviation) 81.22% 18% F 19% F
Risk Adjusted Return 25.78% 50% F 62% D-
Market Capitalization 22.49B 67% D+ 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Specialty Chemicals)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 47.83 23% F 25% F
Price/Book Ratio 3.48 45% F 29% F
Price / Cash Flow Ratio 19.16 47% F 25% F
EV/EBITDA 13.46 56% F 49% F
Management Effectiveness  
Return on Equity 11.14% 40% F 61% D-
Return on Invested Capital 9.49% 43% F 67% D+
Return on Assets 7.02% 56% F 79% C+
Debt to Equity Ratio 42.47% 19% F 28% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.41 22% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector